Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Nuvalent (NASDAQ: NUVL) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc.

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

Nuvalent stockholders will receive $124 per share and the aggregate equity value of the transaction is approximately $10.6 billion. Nuvalent insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Nuvalent by imposing a significant penalty if Nuvalent accepts a competing bid. We are investigating the conduct of the Nuvalent board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

You May Also Be Interested In

• Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
• argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
• Aalberts N.V.: Aalberts reports first half-year results 2026